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Abstract: While several newer AEDs have study data that support monotherapy usage, most possess FDA indications for 
adjunctive treatment of partial onset seizures, leading to their initial (and often persistent) clinical use as adjunctive poly-
therapy for patients with refractory epilepsy. This review considers a practical approach to the appropriate role for poly-
therapy in epilepsy, presents the evidence for AED polytherapy, reviews the mythic but practically reasonable concept of 
“rational polytherapy,” and concludes with practical strategies for avoiding and employing polytherapy in clinical prac-
tice. The appropriate indications for AED polytherapy include transitional polytherapy during titration of a new adjunctive 
AED toward monotherapy or long-term maintenance AED polytherapy in medically refractory epilepsy. 
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INTRODUCTION 
  This is an exciting time to treat patients with epilepsy. 
The advent of an impressive and ever-evolving armamen-
tarium of newer (second- and third-generation) antiepileptic 
agents (AEDs) offers considerable advantages in safety and 
tolerability over older, first generation AEDs. Since 1994, 
eleven AEDs (felbamate, gabapentin, lacosamide, lamo-
trigine, levetiracetam, tiagabine, topiramate, oxcarbazepine, 
pregabalin, rufinamide, and zonisamide) have been approved 
by the Food and Drug Administration (FDA) based on piv-
otal, adjunctive therapy trial designs. While several second-
generation AEDs have study data that support monotherapy 
usage, most possess FDA indications for adjunctive treat-
ment of partial onset seizures, leading to their initial (and 
often persistent) clinical use in polytherapy. There is not yet 
ample evidence to commend “third generation” AEDs (la-
cosamide and rufinamide) for routine use as monotherapy in 
clinical practice, so it is expected that the major use of these 
two newer AEDs will be as adjunctive polytherapy for pa-
tients with refractory epilepsy. 
  This review considers a practical approach to the appro-
priate role for polytherapy in epilepsy, presenting the evi-
dence for AED polytherapy, reviewing the mythic but practi-
cally reasonable concept of “rational polytherapy,” and con-
cluding with practical strategies for avoiding and employing 
polytherapy in clinical practice. The appropriate indications 
for AED polytherapy include transitional polytherapy during 
titration of a new adjunctive AED toward monotherapy or 
long-term maintenance AED polytherapy in medically re-
fractory epilepsy. 
EVIDENCE SUPPORTING POLYTHERAPY 
  Initial AED monotherapy is effective in rendering ap-
proximately 60% of epilepsy patients seizure free [34]. The 
remaining patients are considered medically refractory and  
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are candidates for polytherapy, surgery, or vagus nerve 
stimulation (VNS). Based on this information, at least 14% 
of epilepsy patients will be polytherapy candidates.  
  The American Academy of Neurology/American Epi-
lepsy Society (AAN/AES) Practice Guidelines for the treat-
ment of refractory epilepsy supports the use of second-
generation AEDs for adjunctive treatment of refractory par-
tial-onset seizures in adults [24]. There is ample evidence to 
conclude that nearly all currently marketed AEDs are effec-
tive for the adjunctive treatment of refractory partial seizures 
(except ethosuximide, which is only effective for treatment 
of generalized absence seizures, and in particular lacks effi-
cacy for treatment of partial-onset seizures). However, an 
ideal combination of AEDs has not been identified. While 
meta-analyses results have indicated that lamotrigine, oxcar-
bazepine, and topiramate demonstrate overlapping efficacy; 
direct comparison between individual trials is not possible 
due to important baseline differences in patient demograph-
ics, seizure frequency, disease severity, and inclusion/exclu-
sion criteria [11,24,46].
  Other than the recent randomized, blinded, controlled 
trials of the second- and third-generation AEDs, most poly-
therapy studies were retrospective case series and uncon-
trolled trials. Historically, comparative polytherapy trials 
have found that between 15% to 35% of patients with partial 
seizures become seizure-free, and an additional 12% to 29% 
of patients have a >50% seizure reduction with polytherapy 
[12,15,26,31,41,54,73,79]. The VA I Cooperative Trial, a 
prospective, randomized trial, found that 40% of patients 
failing phenytoin or carbamazepine monotherapy respond to 
polytherapy, with 11% of these patients becoming seizure-
free [48].
WHAT IS RATIONAL POLYTHERAPY? 
  The concept of “rational polytherapy” has held that AED 
combinations with differing mechanisms of action are more 
effective than polytherapy with similar mechanisms of action 
[40,60,66]. An early attempt at rational polytherapy was the 
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mide, arsenic, and picrotoxin); later, co-therapy with pheny-
toin and phenobarbital was commonly used for new-onset 
epilepsy during much of the 20
th century [10,30,74]. Rational 
polytherapy is a logical concept, since the pathophysiology 
of epilepsy is believed to be consequent to two opposing 
types of neural imbalances. Patients may either exhibit ex-
cessive neuronal excitation mediated by pro-glutamatergic 
influences (the principle excitatory neurotransmitter) or a 
failure of inhibition due to decreased GABA-ergic activity 
(the main inhibitory neurotransmitter). AED combinations 
that target over exuberant excitation and insufficient inhibi-
tion would be expected to be more efficacious. Polytherapy 
can produce additive, antagonistic, or synergistic efficacy 
and toxicity [14]. AEDs with similar mechanisms of action 
would be expected to produce merely additive efficacy, 
while AEDs with differing mechanisms of action would be 
expected to be synergistic. Combining AEDs with competi-
tive hepatic enzymatic metabolism or protein binding may 
produce antagonism of one or both AEDs’ efficacy or lead to 
heightened toxicity. AEDs with similar toxicity profiles 
could produce additive or synergistic pharmacodynamic ad-
verse effects. Animal studies utilizing rational polytherapy 
have confirmed that both synergistic efficacy [47] and unex-
pected toxicity [64] may result with varying AED combina-
tions.
  Several pre-clinical experiments suggest synergistic effi-
cacy between specific combinations of AEDs, including: 
phenytoin and phenobarbital; [5] topiramate with carba-
mazepine, felbamate, lamotrigine, phenobarbital, or tiaga-
bine; [14] valproate with phenytoin, carbamazepine, or etho-
suximide; [9,14,16] and AEDs with calcium channel inhibi-
tors or N-methyl d-aspartate (NMDA)-type glutamate recep-
tor antagonists [14]. Levetiracetam may also have synergism 
with several AEDs, particularly valproate [47]. Some AED 
interactions operate in an unpredictable antagonistic fashion; 
for example, ethosuximide and valproate exhibit an in-
creased threshold for toxicity [64]. 
  An example of rational polytherapy would be levetira-
cetam, which modulates pre-synaptic neurotransmitter re-
lease via synaptic vesicle protein 2A (SV2A) binding, [42-
43] plus carbamazepine, a sodium channel ionophore com-
plex inactivator which limits neuronal burst firing and sei-
zure discharge propagation. A review of both polytherapy 
retrospective case series and clinical trials found low-grade 
evidence favoring the combination of sodium channel block-
ing AEDS and those with -aminobutyric acid (GABA) ac-
tivity [17]. On the other hand, combining two GABA mi-
metic drugs or alpha-amino-3-hydroxy-5-methyl-4-isoxa-
zolepropionic acid (AMPA) and N-methyl-D-aspartic acid 
(NMDA) antagonists may enhance efficacy but reduce toler-
ability [17]. Also, despite the theoretical advantages of utiliz-
ing rational polytherapy, in most instances, AED combina-
tions have not demonstrated an improved therapeutic index 
(efficacy/toxicity ratio) over monotherapy [6]. While the 
rational polytherapy approach is certainly sensible and com-
monly employed in clinical practice, there is no evidence 
from clinical trials to support and justify its use. One previ-
ous clinical trial has suggested the potential for drug synergy 
and practical existence of “rational polytherapy” in a clinical 
population [7]. The study enrolled patients receiving one of 
four older AEDs (carbamazepine, phenobarbital, phenytoin, 
or valproate) in monotherapy. Subjects then received adjunc-
tive lamotrigine, and patients responding with a 50% or 
greater seizure reduction were subsequently converted to 
monotherapy with lamotrigine. Efficacy analysis demon-
strated that combination polytherapy with valproate and 
lamotrigine was more effective than other combinations 
(valproate-lamotrigine subgroup 64% responders, carba-
mazepine-lamotrigine 41% responders, phenytoin 38% re-
sponders), suggesting potential synergy between. However, 
the study was not designed to explore synergy between any 
of the drugs, and drug interaction alone (i.e., higher lamo-
trigine plasma concentrations mediated by concurrent val-
proate administration) was an alternative, and more parsimo-
nious explanation, for higher efficacy with a combined val-
proate-lamotrigine regimen [7].  
 Table 1  lists the proposed pharmacological targets of 
commonly used AEDs and serves as a reference for choosing 
combinations of AEDs with complementary mechanisms of 
action with respect to the practical principle of “rational 
polytherapy” (despite a current lack of evidence basis for this 
approach). 
APPROPRIATE POLYTHERAPY: A PRACTICAL 
APPROACH 
  There are no randomized trials to suggest superior effi-
cacy of polytherapy over monotherapy. Since polytherapy 
often affords only modest improvement in efficacy, but sig-
nificant increases in adverse effects, it is sensible to first 
think of strategies for avoiding polytherapy. Most patients 
should receive two sequential trials of AED monotherapy, 
utilizing AEDs with differing mechanisms of action, prior to 
attempting chronic polytherapy.  
  Failure to produce seizure control after even one well-
tolerated, optimally administered monotherapy AED trial is 
an ominous prognostic feature, suggestive of medically re-
fractory epilepsy [35]. After one or two failed trials of mono-
therapy, all patients deserve additional investigations to en-
sure that the correct epilepsy syndrome has been diagnosed, 
and to exclude the possibility of an alternative diagnosis of a 
medical or psychiatric mimicker of epilepsy. In particular, 
the possibility of psychogenic non-epileptic spells (pseu-
doseizures), seen in 20-50% of epilepsy monitoring prac-
tices, needs to be considered, as many such patients present 
after an erroneous diagnosis of epilepsy for several years and 
have been treated with polytherapy, subjecting these patients 
to unnecessary risk and adverse effects [33].
  With refractory partial epilepsy, triage to non-pharma-
cological treatments including epilepsy surgery and vagus 
nerve stimulation (VNS) should be strongly considered, 
since these treatments may afford opportunities to reduce or 
eliminate polytherapy, improve quality of life, and reduce 
cost of treatment [3,4,32,36]. Polytherapy in women of 
childbearing potential is a particular concern given the 
heightened risk of teratogenesis [13,57,59]. A suggested al-
gorithm for initial epilepsy treatment, showing the steps fol-
lowing unsuccessful monotherapy toward either pursuing 
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appropriate non-pharmacologic therapies, is illustrated in 
(Fig. 1). 
  There is no evidence to support polytherapy in new-onset 
epilepsy. Polytherapy is indicated for medically refractory 
epilepsy, and, even then, polytherapy may have two different 
goals and courses is further outlined and discussed in Article 
3 (“Transitional Polytherapy” by Garnett, et al., Fig. 1, pg. 
85 (or whatever the journal page # would be for the run). 
AED management may involve transitional polytherapy 
(conversion to a second-line monotherapy) or chronic main-
tenance polytherapy, possibly requiring additional AED se-
quencing to optimize seizure control and minimize adverse 
effects. Tenets of successful polytherapy include selecting 
co-therapies that lack drug-drug interactions, have a limited 
potential for amplification of adverse effects, and minimize 
total drug load to achieve desired seizure control. A possible 
algorithmic approach to initiating or terminating polytherapy 
is outlined in Fig. (1) on page 85 of the article "Transitional 
Polytheraphy: Tricks of the Trade for Monotherapy to 
Monotherapy AED Conversions" by Garnett, et al. in this 
issue. Examples of some potentially desirable AED combi-
nations (that illustrate a “rational polytherapy” approach) and 
undesirable combinations (that increase the likelihood of 
untoward drug-drug interactions) are shown in Table 2.
Table 1.  Proposed Pharmacological Targets of AEDs 
Drug Sodium 
Channels
Calcium Chan-
nels/Currents
GABA 
Receptors
GABA Syn-
apse
Glutamate 
Receptors
Other
Older AEDs
Benzodiazepines +++ Abuse potential may limit use
Carbamazepine +++ + + Modulates brain adenosine
Phenobarbital/primidone +++ Abuse potential may limit use
Ethosuximide +++ (Modulates T-
type Currents)
Inhibits NADPH-linked aldehyde 
reductase (necessary for gamma-
hydroxybutyrate (GHB) synthesis; 
GHB can induce absences)
Phenytoin +++
Valproate +++ + (Modulates T-type 
Currents)
+
Newer AEDs
Felbamate ++ ++ ++ ++ Idiosyncratic Toxicity limits use
Gabapentin + ++ +
Lacosamide Binds CRMP-2 receptor
Lamotrigine +++ +
Levetiracetam Modulates presynaptic  
neurotransmitter release by SV2A  
receptor binding.
Oxcarbazepine +++ +
Pregabalin ++
Rufinamide ++ +?
Tiagabine +++
Topiramate ++ ++ ++ + ++ +weak carbonic anhydrase  
inhibtion
Zoisamide +++ ++
(Modulates T-type 
Currents)
++facilitates catecholaminergic 
and dopaminergic neurotransmis-
sion; +weak carbonic anhydrase 
inhibition; 
+++ Primary target; ++ Probable target; + Possible target.  
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BEFORE INITIATING POLYTHERAPY 
  When utilizing polytherapy, the clinician must be knowl-
edgeable about the potential for pharmacokinetic and phar-
macodynamic interactions, which influence the risk of de-
veloping adverse effects. While an exhaustive review of drug 
interactions is beyond the scope of this article, a few illustra-
tive scenarios will suffice to make this important point. In 
general, the main pharmacokinetic interactions to consider in 
AED polytherapy are potential cytochrome P450 (CYP) me-
tabolism competition and a high percentage of protein bind-
ing that results in drug displacement. Co-administration of 
the enzyme-inducing AEDs (EIAEDs) (ie, phenobarbital, 
phenytoin, or carbamazepine) with inducible AEDs (such as 
lamotrigine, oxcarbazepine, tiagabine, topiramate, or zoni-
samide) hastens the metabolism of the latter, reducing drug 
concentrations and efficacy. Conversely, when valproate, an 
inhibitor of lamotrigine glucuronidation and clearance is 
given with lamotrigine, there is a greater chance of serious 
rash than when lamotrigine is given with EIAEDs [1,53]. 
Two recent studies of vulnerable institutionalized patients 
well illustrate the complex pharmacokinetic issues that can 
arise in polytherapy. In these studies of elderly nursing home 
and multiply handicapped patients, common use of undesir-
able pharmacokinetic AED combinations was found, espe-
cially phenytoin/phenobarbital polytherapy [27,45]. The in-
teractions between these two AEDs are bidirectional, com-
plex, and variable, often leading to unpredictable increases 
or decreases in drug concentrations. In an institutionalized 
patient population with common comorbid hypoalbumine-
mia, free phenytoin levels enable appropriate co-therapy 
adjustments and thereby avoid toxicity. In these and all pa-
tients, the goal should be to minimize the likelihood of com-
plex drug interactions. Rather than rote memorization of a 
long list of potential drugs interacting with one another, it is 
more important and practical to have a working understand-
ing of mechanisms for each drugs to interact with others that 
may allow one to predict or anticipate interactions; details on 
specific likely interactions can always be gleaned (and when 
in doubt, should be actively sought by practitioners) from 
comprehensive references such as the Physician’s Desk Ref-
erence (PDR), or online with Micromedix. Table 3 includes 
mechanisms for common AED interactions that are crucial to 
understand and be familiar with for use of the AEDs in clini-
cal practice. For further references on these important con-
siderations involved with initiating and maintaining poly-
therapy, the reader is referred to two recently published ex-
tensive reviews of AED drug interactions [22,58].  
  Pharmacodynamic adverse effects, such as dose-related 
neurotoxic and cognitive side effects, are especially difficult 
to avoid when using polytherapy [20]. Cognitive impairment 
is commonly seen with polytherapy and is often subtle and 
difficult to identify without specifically questioning the pa-
tient. While standard office assessment of cognition often 
shows minimal impact, detailed neuropsychological and 
electrophysiological measures may show impairments in 
attention, concentration, executive function, and memory in 
patients receiving AED therapy [50-52,62,70,77,78]. Some 
adverse effects such as sedation, cognitive impairments, gait 
disturbance, and hair changes are consistently underreported 
unless patients are specifically questioned about the presence 
or absence of these symptoms. Routine use of adverse event 
screening instruments during office visits aids in the identifi-
cation of patient adverse effects that limit quality of life, 
especially for patients receiving polytherapy [25]. Readers 
are referred to the next article in this issue (“Minimizing 
Adverse Effects in Epilepsy Care”) for discussion and refer-
ences on monitoring and reducing adverse effects of AEDs. 
  Some AEDs have a greater tendency to cause pharma-
codynamic adverse effects when used in polytherapy; for 
example, there is an increase in the incidence of adverse ef-
fects if topiramate is utilized as adjunctive therapy than when 
it is administered as monotherapy [55,56,61,63]. Thus, be-
fore initiating polytherapy in a patient with epilepsy, the cli-
nician should design a patient specific AED regimen that 
minimizes adverse events and drug interactions (by taking 
into account AED specific pharmacokinetics and pharma-
codynamics), while maximizing efficacy, and continuously 
monitor that patient for signs of toxicity.  
HOW TO INITIATE POLYTHERAPY 
  A commonly employed method of introducing an adjunc-
tive drug is to hold the current AED at a constant dose, then 
gradually titrate the new AED to the target dose [72]. Rapid 
dose escalation has been associated with AED therapy dis-
continuation, so most AEDs should be initiated at a low 
dose, and increased slowly to maximize patient tolerability 
and avoid dose related side effects (eg, drowsiness, dizzi-
ness, ataxia, or visual problems). If adverse effects emerge 
during the titration of the adjunctive AED, there are two pos-
sible approaches: 1) reduce the baseline AED to “make 
room” for continued titration of adjunctive therapy; dose-
related adverse effects may be pharmacodynamically medi-
ated by both AEDs, not solely due to the new AED (ie, 
flexible dose approach) [56] or 2) reduce the new AED; 
thereby accepting a lower target dose of this therapy (similar 
to the fixed dose approach utilized in most partial seizure 
adjunctive therapy clinical trials). Recently, a randomized, 
prospective, adjunctive topiramate trial addressed adverse 
effects emerging during adjunctive AED titration and 
Fig. (1). Therapeutic Triage in Epilepsy Care. Newly diagnosed 
epilepsy patients are most appropriately treated with antiepileptic 
drug monotherapy. Following failure of a second monotherapy, 
clinicians should implement courses of sequential chronic mainte-
nance polytherapy and intensive evaluation to ensure correct epi-
lepsy syndrome diagnosis and exclusion of nonepileptic spells. Pre-
surgical evaluation with seizure-protocol magnetic resonance imag-
ing (MRI) of the brain and ictal video-EEG recording of the pa-
tient’s habitual clinical spells should also be strongly considered to 
evaluate the patient’s potential to benefit from non-pharmacologic 
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Table 2.  Examples of Desirable and Undesirable AED Combinations 
Combination Desirability Rationale
Phenytoin or Carbamazepine, plus
Lamotrigine –
EIAEDs decrease LTG, heightened pharmacodynamic neurotoxic ad-
verse effects
Oxcarbazepine –
EIAEDs decrease OXC, OXC inhibits CYP 2C19 and may increase 
PHT concentrations; increased neurotoxic adverse effects
Topiramate –
EIAEDs decrease TPM, TPM inhibits CYP 2C19 and may increase 
PHT concentrations; increased neurotoxic adverse effects
Levetiracetam + Possible synergism with CBZ
Lamotrigine or Oxcarbazepine, plus
Gabapentin ++ Potential synergism
Pregabalin ++ Potential synergism
Levetiracetam ++ Potential synergism
Topiramate + Potential synergism
Zonisamide +/– Possible additive effects, similar principle MOA
Valproate or divalproex, plus
Phenytoin –
Increased free PHT fraction and neurotoxic adverse effects; however, 
retrospective case series suggest synergism
Carbamazepine – Valproate increases CBZ-epoxide, similar principle MOA
Lamotrigine +/–
Controlled clinical trial evidence for efficacy; however, increased risk 
of rash
Topiramate +/–
Hypothetically may offset weight gain adverse effects; however, in-
crease in neurotoxic adverse effects
Levetiracetam ++ Possible synergism
Zonisamide + Possible synergism
+ Potentially desirable combination; ++ Desirable combination. 
– Potentially undesirable combination; – – Undesirable combination. 
+ / – Data are conflicting. 
Table 3.  Common Representative AED Interactions in Clinical Practice 
AED Mediates CYP 
Induction
Mediates CYP 
Inhibition
Metabolism 
Inducible by  
CYP Enzyme
Metabolism 
Inhibited at 
CYP Enzyme
Protein 
Binding
Other
Older AEDs
Carbamazepine +++ ++ ++
(+Autoinduction)
++ ++ -
Ethosuximide - - ++ ++ - -
Phenobarbital ++ - + + - + (Antacids 
decrease absorption)
Phenytoin +++ - + ++ +++ + (Antacids 
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(Table 3. Contd….) 
AED Mediates CYP 
Induction
Mediates CYP 
Inhibition
Metabolism 
Inducible by  
CYP Enzyme
Metabolism 
Inhibited at 
CYP Enzyme
Protein 
Binding
Other
Primidone ++ + + + - -
Valproate - ++ - - +++ + (Drugs impacting 
glucuronidation may 
impact valproate 
concentrations; Food 
slows absorption)
Newer AEDs
Felbamate ++ + +++ - - + (Inhibits beta  
oxidation (increasing 
valproate  
concentrations)
Gabapentin - - - - - saturable absorption at
doses > 1800 mg/day
Lacosamide - - - - - -
Lamotrigine +/- - +++ - - +++ (drugs impacting 
glucuronidation such 
as valproate affect 
lamotrigine  
concentrations)
Levetiracetam - - - - - -
Oxcarbazepine + (at doses 
above 1800 
mg/day, ++)
++ (at high  
phenytoin  
concentrations)
++ - - -
Pregabalin - - - - - -
Rufinamide + - + - - +++ (valproate  
increases rufinamide 
concentrations by up 
to 70%)
Tiagabine - - +++ - + -
Topiramate + (>200 mg, 
+++)
++ (at high  
phenytoin  
concentrations)
+++ - - -
Zonisamide - - +++ + - -
Key:  +++ = principle mechanism for drug interactions with this drug; ++ = secondary mechanism of drug interactions with this drug;  +  = possible but less common mechanism of 
interaction with this drug. 
assessed whether a flexible or fixed titration approach was 
most tolerable [56]. Patients were randomized to one of two 
treatment arms: 1) a “Flex Dose” titration group, in which 
investigators were permitted to reduce the baseline AED 
dose as needed to permit titration of adjunctive topiramate; 
and 2) a “Fixed Dose” titration group, which did not allow 
investigators to adjust the baseline AED dose. If the investi-
gators needed to adjust baseline co-therapy, the patient was 
removed from randomized treatment. The primary study 
endpoint was the percentage of patients dropping-out of ran-
domized treatment due to adverse effects. The Flex Dose 
group achieved higher target doses of adjunctive topiramate, 
while the Fixed Dose group had nearly twice as many sub-
jects drop-out because of intolerable adverse effects. This 
data suggests that reduction of the baseline AED dosage is a 
superior approach for minimizing adverse effects that 
emerge during the titration of a new adjunctive therapy, ena-
bling an adequate therapeutic trial of the new adjunctive 
AED. An adjunctive AED can be further increased as needed 
to achieve optimal therapeutic doses. In many instances, it is 
sensible to transition to monotherapy with the newly added 
AED, by discontinuing the baseline AED [2]. Some advocate 
initial lowering of the baseline AED prior to initiating a new 
adjunctive AED [66]. While this approach may improve the 
patient’s ability to tolerate the new adjunctive AED, the risk 
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leading a recently convened expert consensus panel of epi-
leptologists to instead recommend holding an initial baseline 
drug at a constant dose during titration of a new adjunctive 
AED until the target dose of that drug is reached, followed 
by taper of the primary baseline drug unless adverse effects 
occur, in which case tapering the primary drug can be   
tapered and withdrawn [72]. An approach of “criss-crossing” 
and existing primary the new adjunctive AED (i.e., titrating 
the new AED while concomitantly withdrawing an existing 
baseline AED) is probably best reserved for patients who   
are known to have a heightened sensitivity to AED adverse  
effects. 
  Similar decisions about drug titration need to be made 
when considering the addition of a third AED to a patient’s 
regimen, or when fourth or fifth adjunctive AEDs are con-
templated. Use of more than two AEDs is generally discour-
aged due to an increased likelihood of pharmacokinetic and 
pharmacodynamic AED interactions with each additional 
AED. A recent, large, retrospective study suggested that two 
or three AEDs may effectively control seizures, but four or 
more AEDs were not beneficial [69]. Data from previous 
clinical trials suggests that between 20% to 50% of patients 
benefit from triple AED polytherapy by achieving a 50% or 
greater reduction of seizures [20,29,49]. Unfortunately, cur-
rently available data does not provide conclusive evidence 
on how to initiate the third AED. One reasonable option is to 
maintain the baseline AED regimens, titrate the third AED to 
a target dose, and then taper off the least effective AED. If 
an adverse effect develops during titration of the newest 
AED, immediately taper off the least effective AED to im-
prove tolerability. Alternatively, if one of the AEDs in the 
regimen can be singled out as ineffective or poorly tolerated, 
consider titrating the new AED while simultaneously taper-
ing the ineffective or intolerable AED. 
WHEN POLYTHERAPY BECOMES OVER-TREAT-
MENT  
  Polytherapy has been identified as one means of over-
treatment in epilepsy. Over-treatment may be defined as an 
excessive number or amount of AED(s) given, that results in 
a suboptimal risk-to-benefit balance [20,67]. Tapering of one 
or more AEDs can be successfully accomplished in many 
patients receiving chronic polytherapy, without substantial 
loss of seizure control [2,8]. There are many reasons to con-
sider reducing polytherapy, including reducing the risk of 
serious adverse effects, minimizing drug interactions [60], 
and decreasing costs [4]. Uncontrolled seizures and poly-
therapy have been linked to decreased quality of life [75]. 
Paradoxically, over-treatment with AEDs can occasionally 
result in an increase in seizure activity, and reduction in 
polytherapy has been shown to lead to improved seizure con-
trol in approximately two-thirds of patients [8,20].  
  Considerable research has demonstrated that the most 
deleterious outcome associated with polytherapy is an in-
creased risk of adverse effects (eg, sudden unexplained death 
in epilepsy patients (SUDEP), memory complaints, depres-
sion, and fatigue) due to pharmacodynamic dose-related neu-
rotoxic effects, drug interactions, additive or synergistic drug 
related toxicities, and teratogenicity [1,13,57,59,67]. Poly-
therapy may be less tolerable than monotherapy because of a 
higher total drug load [16,18]. Most polytherapy studies have 
not controlled for total drug load [16,17,20]. Total drug load 
is the sum of the prescribed daily doses (PDD) of the AEDs 
that an individual patient is receiving. If the ratio of the PDD 
and the average effective or defined daily dose (DDD) of the 
AED exceeds 2, patients are more likely to exhibit neuro-
logical adverse effects [16,21,39]. DDD values assigned by 
the World Health Organization (WHO) for the AEDs are 
listed in Table 4 [16,81]. Whether using one or multiple 
AEDs, the PDD/DDD ratio should be below 2 to reduce the 
likelihood of neurological side effects; when using more than 
one AED, doses should generally be below or at the DDD 
for each individual drug to maximize tolerability for the pa-
tient. 
  Data comparing tolerability of monotherapy and poly-
therapy support the theory that equalizing total drug load of 
monotherapy to polytherapy leads to similar adverse effects 
with both approaches [19,39]. A cohort study of patients 
receiving either monotherapy or polytherapy in comparable 
drug loads showed no difference in perceived adverse effects 
[39]. A prospective, randomized study comparing carba-
mazepine alone to carbamazepine plus valproate, using com-
parable drug loads, found no difference in tolerability or ef-
ficacy between the two groups [18]. This study demonstrates 
that equalizing drug loads between monotherapy and poly-
therapy regimens may improve patient tolerability of poly-
therapy and provide a standardized method to compare the 
efficacy of monotherapy and polytherapy regimens. This 
study could not conclude whether monotherapy is as effec-
tive as polytherapy since it was powered to assess tolerability 
(primary endpoint), and was not designed to detect a differ-
ence in seizure control. The drug load concept can be applied 
to clinical practice; when the addition of another AED is 
required, the PDD/DDD ratio provides a guidepost for the 
total dose that a patient would be most likely to tolerate. Po-
tential problems with the total drug load concept include the 
failure to predict non-linear efficacy or tolerability due to 
pharmacodynamic drug interactions, and the inability to ac-
count for various pharmacokinetic drug interactions, includ-
ing protein binding displacement and cytochrome dependent 
induction or inhibition [16]. Further research regarding ap-
plication and utility of the drug load concept in clinical prac-
tice is necessary. Also, since the drug load concept has not 
been frequently considered in AED polytherapy, an attrac-
tive and tantalizing prospect for future polytherapy research 
would be the design of future randomized controlled trials 
comparing the efficacy and tolerability of polytherapy with 
monotherapy in newly diagnosed and refractory epilepsies, 
controlling for equivalent drug loads between monotherapy 
and polytherapy groups. 
REDUCING UNNECESSARY POLYTHERAPY 
  Polytherapy continues to be common practice, especially 
in institutionalized epilepsy patients. Practitioners should 
regularly and critically re-examine the necessity of AED 
polytherapy in all patients, but especially the elderly, the 
institutionalized, children, and women, since they are espe-
cially vulnerable to undesirable combinations of AED and 
non-AED polytherapy and subsequent adverse effects posing 
significant risks [13,57,59]. Women of child bearing poten-Truly “Rational” Polytherapy  Current Neuropharmacology, 2009, Vol. 7, No. 2    103
tial treated with polytherapy have an increased risk of giving 
birth to children with major congenital malformations if they 
become pregnant [13,59]. The effects of polytherapy on the 
developmental outcome of children born to mothers with 
epilepsy is unknown. Polytherapy has been associated with 
decreased patient compliance, reduced quality of life, and 
increased costs. Recently, polytherapy was also demon-
strated to be a predictive factor for reduced bone mineral 
density in patients with epilepsy [23]. Maternal AED poly-
therapy has also been correlated with a heightened risk for 
cognitive and motor developmental delays in infants exposed 
in utero [76]. Therefore, reserving polytherapy for patients 
who have no other alternative is reasonable. 
  When reduction of polytherapy has been unsuccessful 
due to increased breakthrough seizures, another means of 
enabling polytherapy reduction is to reconsider non-pharma-
cologic approaches to augment management of the patient’s 
epilepsy. Additional diagnostic testing to explore candidacy 
for epilepsy surgery or VNS therapy should be strongly con-
sidered (as per Fig. 1 ), since these treatments may afford 
patients a greater chance of reducing or eliminating poly-
therapy. Several retrospective studies comparing pre-opera-
tive to post-operative AED regimens following successful 
anterior temporal lobectomy consistently report successful 
elimination of polytherapy in the majority of patients, [44,65, 
71,80] and a prospective randomized trial of carbamazepine 
monotherapy versus preoperative polytherapy demonstrated 
equivalent efficacy and reduced adverse effects in the mono-
therapy treatment group [32]. With adjunctive VNS therapy, 
many patients have been able to decrease total drug load by 
reducing the total number of AEDs used or decreased doses 
of individual AEDs without seizure exacerbation [38].  
CONCLUSION 
  Monotherapy is usually preferred over polytherapy when-
ever possible in epilepsy care. However, a substantial num-
ber of patients with intractable epilepsy may respond to AED 
polytherapy. Appropriate uses of more than one AED in-
clude transitional polytherapy during conversion to a new 
Table 4.  World Health Organization (WHO) Defined Daily Doses (DDD) Index Useful for Drug Load Calculations for the AEDs 
AED DDD/mg DDD/g ATC Code
Older AEDs
Carbamazepine 1000 1.0 N03AF01
Clonazepam 8 0.008 N03AE01
Ethosuximide 1250 1.25 N03AD01
Phenobarbital 100 0.1 N03AA02
Phenytoin 300 0.3 N03AB02
Primidone 1250 1.25 N03AA03
Newer AEDs
Felbamate 2400 2.4 N03AX10
Gabapentin 1800 1.8 N03AX12
Lacosamide n.a. n.a. N03AX18
Lamotrigine 300 0.3 N03AX09
Levetiracetam 1500 1.5 N03AX14
Oxcarbazepine 1000 1.0 N03AF02
Pregabalin 300 0.3 N03AX16
Rufinamide 1400 1.4 N03AF03
Tiagabine 30 0.03 N03AG06
Topiramate 300 0.3 N03AX11
Valproate 1500 1.5 N03AG01
Vigabatrin 2000 2.0 N03AG04
Zonisamide 200 0.2 N03AX15
ATC Code = Anatomical Therapeutic Chemical Classification. 
n.a. = not currently available. 
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monotherapy, and chronic maintenance polytherapy in re-
fractory patients. When a patient becomes seizure-free while 
receiving polytherapy, it may be possible to taper and gradu-
ally discontinue the baseline AED which has been previously 
ineffective or poorly tolerated. Randomized trials investigat-
ing rational polytherapy are needed to assess which combi-
nations are most efficacious. AED treatment should be ad-
justed based on PDD/DDD ratios less than 2 to maximize 
tolerability; patient and drug specific characteristics should 
be considered to minimize drug-drug and drug-disease inter-
actions and limit the incidence of adverse effects. Intractable 
epilepsy patients should be continuously reassessed; poly-
therapy should be maintained only when improved efficacy 
outweighs adverse effects. Eliminating unnecessary poly-
therapy benefits many patients by reducing adverse effects, 
drug interactions, and cost. 
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